1996
DOI: 10.1016/0196-9781(95)02131-0
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of the satiating effect of the CCKA receptor agonist A71378 with CCK-8S

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

1996
1996
2005
2005

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(3 citation statements)
references
References 6 publications
0
3
0
Order By: Relevance
“…Studies on CCK-8 analogues indicated that Asp N-methylation is responsible for CCK-A receptor selectivity. The duration of the anorectic action of 58 in vivo was greater than that of CCK-8 …”
Section: Mechanisms Targeting the Gastrointestinal Tractmentioning
confidence: 90%
See 1 more Smart Citation
“…Studies on CCK-8 analogues indicated that Asp N-methylation is responsible for CCK-A receptor selectivity. The duration of the anorectic action of 58 in vivo was greater than that of CCK-8 …”
Section: Mechanisms Targeting the Gastrointestinal Tractmentioning
confidence: 90%
“…The duration of the anorectic action of 58 in vivo was greater than that of CCK-8. 177 Replacement of the methionine residue of Boc-CCK-4 (Boc-Trp-Met-Asp-Phe-NH 2 ) with side-chain-substituted Lys derivatives resulted in A 71623 (59). 178 This tetrapeptide is a potent and selective agonist at the CCK-A receptor and is functionally equivalent to CCK-8 with enhanced metabolic stability.…”
Section: Mechanisms Targeting the Gastrointestinal Tractmentioning
confidence: 99%
“…It has been reasoned that the development of biologically stable CCK 1 receptor agonists, which can be administered orally, may provide a means of inhibiting food intake and reducing body weight. There are two main classes, the tetra‐ and hexapeptides and the 1,5‐benzodiazepine CCK 1 receptor agonists, which, like CCK, have been shown to inhibit energy intake in rat models when administered acutely (87–91). In the only report relating to the effects of a CCK 1 receptor agonist, GW181771, in humans, there was a dose‐dependent decrease in energy intake over 24 h in obese women (http://www.gsk.com/press_archive).…”
Section: Therapeutic Potential For Cholecystokinin or Activation Of mentioning
confidence: 99%